Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Equivalents (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Cash & Equivalents data on record, last reported at $22.5 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 20.8% year-over-year to $22.5 million; the TTM value through Sep 2025 reached $22.5 million, down 20.8%, while the annual FY2024 figure was $38.3 million, 93.26% up from the prior year.
  • Cash & Equivalents reached $22.5 million in Q3 2025 per ASMB's latest filing, down from $24.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $78.3 million in Q1 2021 and bottomed at $18.1 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $39.0 million, with a median of $38.3 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: crashed 62.15% in 2023, then skyrocketed 93.26% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $45.6 million in 2021, then grew by 14.88% to $52.4 million in 2022, then plummeted by 62.15% to $19.8 million in 2023, then surged by 93.26% to $38.3 million in 2024, then plummeted by 41.23% to $22.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $22.5 million in Q3 2025, $24.0 million in Q2 2025, and $23.4 million in Q1 2025.